Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- levacetylleucine
- Ubrelvy (ubrogepant)
Interactions between your drugs
ubrogepant levacetylleucine
Applies to: Ubrelvy (ubrogepant), levacetylleucine
Levacetylleucine can increase the blood levels of ubrogepant. This may increase side effects such as nausea and sleepiness. The usual recommended dose for migraine is 50 mg in individuals who are receiving treatment with levacetylleucine. A second dose, if needed, may be taken 2 hours after the initial dose. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a different dose to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
ubrogepant food
Applies to: Ubrelvy (ubrogepant)
Grapefruit and grapefruit juice can increase the blood levels of ubrogepant. This may increase side effects such as nausea and sleepiness. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe an alternative that does not interact, or you may need a different dose to safely use your medication with grapefruit and grapefruit juice. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to professional interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Miplyffa
Miplyffa (arimoclomol) is a medication for Niemann-Pick disease type C (NPC) to help stop disease ...
Aqneursa
Aqneursa information from Drugs.com, includes Aqneursa side effects, interactions and indications.
Amvuttra
Amvuttra is used to treat polyneuropathy associated with hereditary transthyretin-mediated ...
Cerdelga
Cerdelga (eliglustat) is used to treat mild to moderate Type 1 Gaucher Disease. Includes Cerdelga ...
Crysvita
Crysvita is used for familial hypophosphatemia, osteomalacia, X-Linked Hypophosphatemia
Galafold
Galafold (migalastat) is used to treat Fabry disease. Includes Galafold side effects, interactions ...
Givlaari
Givlaari injection is used for acute hepatic porphyria (AHP) to reduce the number of acute attacks ...
Iqirvo
Iqirvo (elafibranor) is used to treat primary biliary cholangitis (PBC) in combination with ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.